Van Goor, Fredrick F.,Burton, William Lawrence,Huang, Chien-Jung,Negulescu, Paul Adrian,Yu, Haihui
申请号：
AU2011255237
公开号：
AU2011255237A1
申请日:
2011.05.20
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5- hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
